Bamlanivimab and etesevimab are intended for use in COVID patients at high risk of disease progression More: EMA ends rolling review for COVID antibodies Source: News
read moreNovartis teams with advocacy group to bring visibility to atherosclerotic cardiovascular disease sharon.coey Tue, 11/02/2021 – 12:57 More: Novartis teams with advocacy group to bring visibility to atherosclerotic cardiovascular disease Source: fierce
read morePfizer ups 2021 COVID-19 vaccine sales once again, but it remains coy about future sales kdunleavy Tue, 11/02/2021 – 12:18 More: Pfizer ups 2021 COVID-19 vaccine sales once again, but it remains coy about future sales Source: fierce
read moreAbbVie’s Vuity snags FDA approval as first eye drop for presbyopia, with rival Eyenovia closely behind aliu Tue, 11/02/2021 – 11:42 More: AbbVie’s Vuity snags FDA approval as first eye drop for presbyopia, with rival Eyenovia closely behind Source: fierce
read moreIncyte combats insurance hurdles for eczema cream Opzelura, but dermatologists fully on board: exec aliu Tue, 11/02/2021 – 10:08 More: Incyte combats insurance hurdles for eczema cream Opzelura, but dermatologists fully on board: exec Source: fierce
read moreJohnson & Johnson, AbbVie, Teva and Endo score industry’s first opioid trial win esagonowsky Tue, 11/02/2021 – 09:56 More: Johnson & Johnson, AbbVie, Teva and Endo score industry's first opioid trial win Source: fierce
read more© 1994 - 2026 B.M. Pharmaceuticals